ITGAE (Integrin Subunit Alpha E)

Increased frequency of CD103+ T cells is associated with metastatic non-haematopoietic malignancies in excisional and core needle biopsies of clinically concerning lymphadenopathy.

SAM.1 hydrogel acted as a two-in-one scaffold, controlled release and an immunomodulatory agent, to enhance the persistence and antitumor function of Vγ9Vδ2 T cells. This strategy provided a new paradigm for γδ T-cell-based immunotherapy in melanoma.

Our findings reveal an epigenetic-Hippo-immunomodulatory axis in osteosarcoma that also extends to other sarcomas, providing a rationale for incorporating epigenetic preconditioning with immunotherapy to improve patient outcomes and pointing towards novel biomarkers for treatment guidance.

P1/2, N=50, Recruiting, Universita' Degli Studi Di Perugia | Not yet recruiting --> Recruiting

In peripheral tissues, elevated Tbet expression failed to overcome the requirement for Ets1 in activation-induced interferon γ-production but instead drove increased cytotoxic effector protein expression. Our findings establish Ets1 as a central regulator of iNKT1 cell homeostasis, enforcing a tissue-resident identity in the thymus and supporting context-appropriate effector function.

T cells interacting with PD-L1+ tumor cells may be characterized as PD-1+ CD8+ TRM cells. A closer distance between the two enhances therapeutic efficacy and may be associated with density of hypoxic CD8 cells.

Our study delineates the clinical relevance of heterogeneous immune cell subsets in ICI-treated mNSCLC, aiding the development of targeted therapeutic strategies.

Effective anti-tumor immunosurveillance relies on the direct engagement of naïve TRM cells with tumor cells. These findings highlight the potential of PD-1-targeted immunotherapies to remodel the spatial proximity of the tumor microenvironment, potentially promoting the redistribution of effector cells into tumor-proximal regions.

Notably, GA-NPs@DCV also promotes the generation of tissue-resident memory T cells (TRM, CD8+CD103+ cells) within tumor tissue, effectively inducing long-term protective immunity. Overall, these findings identify GA-NPs@DCV as an effective personalized nanovaccine that can simultaneously deliver tumor antigens and the Stat3 inhibitor GA to the tumor microenvironment to exert potent antitumor effects, providing a promising immunotherapeutic strategy for ovarian cancer.

RAISE exhibited efficient tumor control, and when combined with anti-PD-1 immunotherapy, RAISE inhibited lung metastasis, generated systemic immune responses, and induced immune memory. Taken together, RAISE can be utilized to trigger long-term systemic antitumor immunity for improving tumor immunotherapy.

This study demonstrates that combining stereotactic body radiotherapy with pembrolizumab is feasible and yields promising response rates in patients with advanced, previously treated hepatocellular carcinoma, including those with macrovascular invasion - a group typically associated with poor outcomes. These findings support further evaluation of this integrated approach and provide important guidance for the design of future clinical trials aimed at improving outcomes in advanced hepatocellular carcinoma.

Understanding how different expanded TIL subgroups impact treatment response helps to recognize new biomarkers and therapeutic targets. This review investigates functions of TIL populations beyond the traditional markers like CD3 and CD8 across different cancers while concentrating on predictive outcomes in immunotherapy.